NASDAQ: PTGX ยท Biotechnology
Protagonist Therapeutics (PTGX) fair value and price range
As of 3 Oct 2026, Faircurve's model values Protagonist Therapeutics (PTGX) at $140.47 a share. The stock last closed at $140.06, which puts the model's fair value 0.3% above the price. The inputs behind this valuation are under review, so no verdict is shown.
- The stock trades on multiples far outside what a peer comparison can handle, so the fair value is a rough guide only.
Revalued . Price is the close of 2 Oct 2026. Protagonist Therapeutics, Inc.
What price range does the model give PTGX?
The calibrated range for PTGX over 63 trading days is $117.20 to $170.29. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $109.98 to $178.82. In 50% of the simulations the fair value came out above the price the model ran on.
How does PTGX compare with similar companies?
The companies in biotechnology closest to Protagonist Therapeutics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | $64.19 | $54.39 | -15.3% | Data under review |
| KRYS Krystal Biotech, Inc. | $322.28 | $351.88 | +9.2% | Fairly valued |
| TGTX TG Therapeutics, Inc. | $54.29 | $63.42 | +16.8% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $65.60 | $53.08 | -19.1% | Low evidence grade |
| BMRN BioMarin Pharmaceutical Inc. | $57.18 | $67.58 | +18.2% | Undervalued |
| TECH Bio-Techne Corporation | $72.40 | $69.01 | -4.7% | Fairly valued |
| HALO Halozyme Therapeutics, Inc. | $109.86 | $108.08 | -1.6% | Fairly valued |
| LGND Ligand Pharmaceuticals Incorporated | $302.96 | $304.32 | +0.4% | Low evidence grade |
When does PTGX report earnings, and how has the stock reacted?
Protagonist Therapeutics's next earnings report is scheduled for 5 Nov 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 7.4% in either direction through the nearest expiry, about 13 days out. That is the size the market is pricing, not a direction.
How PTGX moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 5.0%.
| Report date | Two session move |
|---|---|
| 5 Aug 2026 | +7.6% |
| 5 May 2026 | +4.5% |
| 25 Feb 2026 | +1.1% |
| 6 Nov 2025 | +2.1% |
| 6 Aug 2025 | -5.5% |
| 6 May 2025 | +25.3% |
| 21 Feb 2025 | -6.5% |
| 7 Nov 2024 | -2.9% |
Protagonist Therapeutics at a glance
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies.
- Market value
- $9.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $277M
- Consensus revenue growth, next fiscal year
- +1081.0%
- Analysts with estimates
- 8
- Beta to the US market
- 0.01
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Protagonist Therapeutics on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for PTGX was $142.28. As of 3 Oct 2026 it is $140.47, a change of -1.3%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Protagonist Therapeutics's valuation
Is Protagonist Therapeutics stock undervalued or overvalued?
Faircurve's model puts PTGX's fair value at $140.47 a share against a last close of $140.06, as of 3 Oct 2026. The inputs behind this valuation are under review, so no verdict is shown.
What is PTGX's fair value?
$140.47 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $109.98 to $178.82.
What price range does the model give PTGX?
$117.20 to $170.29 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does Protagonist Therapeutics report earnings next?
The next report is scheduled for 5 Nov 2026. Companies can move their dates.
How much has PTGX moved on past earnings reports?
Across its last 8 reports the median two session move was 5.0%, ignoring direction. The largest was +25.3% around the report of 6 May 2025.
How confident is the model in this valuation?
The model's evidence grade for PTGX is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.